Comvita to unveil research
March 17, 2016
NATURAL health
company Comvita
has hailed the
results of new
research which
indicates that
olive leaf extract
can help reduce
cardiovascular risk
factors.
Published in the
European Journal
of Nutrition just
last week, the
60-person study
was a randomised,
double-blind,
placebo-controlled
cross-over trial
in which prehypertensive
participants took olive leaf extract
in liquid form or placebo daily for
six weeks, and then crossed over
to the other treatment arm for a
further six weeks.
The outcome was favourable
improvements in several
cardiovascular risk factors including
a reduction in diastolic blood
pressure which may in turn be
associated with a 9-14% reduction
in cardiovascular risk.
Although researchers have
previously shown olive leaf extract
has a positive short term effect
on CVD risk factors, this is the first
study to show the beneficial effects
over a longer timeframe.
A Clinical Bites session at the APP
conference on the Gold Coast will
discuss the results further on Fri
this week, with presenter Professor
Ian Rowland from the University
of Reading pictured above right
at an event last night on the
Gold Coast with Ralf Schlothauer,
chief technical officer of Comvita
Innovation Limited, the company’s
research arm.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Mar 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Mar 16
